FINWIRES · TerminalLIVE
FINWIRES

Druzhba Pipeline Oil Flows to Slovakia Resume After 3-Month Disruption

By

-- Crude oil supplies to Slovakia via the Druzhba pipeline have resumed as of 2 a.m. local time, Deputy Prime Minister of Slovakia Denisa Sakova said Thursday in a social media post.

The oil intake, she said, was being carried out in accordance with an agreed plan, without actually stating what this plan was.

This brings an end to the three-month-long standoff, which began with a Russian drone strike against the pipeline's section in Ukrainian in January, according to a report by Politico.

Both Slovakia and Hungary had accused Ukraine of dragging its feet to make repairs to sections of the damaged pipeline that was within its borders.

Slovakia's Prime Minister Robert Fico said that while he welcomed the resumption of flows via the pipeline, he also believed that this proves that there was no damage. This was a politically motivated blockage. "It wasn't damaged, and the Druzhba pipeline and oil were used as tools in a geopolitical struggle," he said.

Hungarian Prime Minister Viktor Orban had blocked the EU's 90 billion euro ($105.14 billion) loan to Ukraine using his veto powers, demanding that oil flows via the pipeline be restored first.

Related Articles

Australia

Mizuho Securities Raises Price Target on Apellis Pharmaceuticals to $41 From $20, Maintains Neutral Rating

Apellis Pharmaceuticals (APLS) has an average rating of hold and mean price target of $40.82, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $40.95, Change: $-0.05, Percent Change: -0.11%

$APLS
Research

Mizuho Securities Downgrades Terns Pharmaceuticals to Neutral From Outperform, Trims Price Target to $53 From $54

Terns Pharmaceuticals (TERN) has an average rating of hold and mean price target of $53, according to analysts polled by FactSet.

$TERN
Research

Research Alert: CFRA Reiterates Buy Opinion On Shares Of Booking Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price by $8 to $196, 19x our 2026 EPS estimate (unchanged) and a discount to its 23x five-year average forward multiple, reflecting geopolitical risks. We lower our 2026 EPS to $10.33 from $10.74 and 2027's to $11.58 from $12.07, primarily reflecting lower gross bookings growth from the Middle East conflict. We maintain our Buy opinion as shares are undervalued given long-term competitive strengths and temporary geopolitical headwinds. The company's Connected Trip platform and Genius loyalty program are supporting higher-margin direct bookings, suggesting AI initiatives are strengthening consumer engagement rather than disintermediating the platform. Strong free cash flow supports future shareholder returns, including $3.6 billion in Q1 buybacks. While the Middle East conflict will impact Q2 bookings, BKNG has a history of seeing travel rebound following geopolitical or economic disruptions. U.S. room night growth accelerated in Q1 to a low-teens range, providing near-term momentum.

$BKNG